Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immuneering Corporation - Class A Common Stock
(NQ:
IMRX
)
3.710
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuneering Corporation - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Why Is Immuneering Stock Trading Higher On Tuesday?
↗
January 07, 2025
Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans.
Via
Benzinga
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
January 07, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore
↗
December 20, 2024
The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.
Via
Talk Markets
Topics
Stocks / Equities
Immuneering Launches Pancreatic Cancer Advisory Board
December 19, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Why is Immuneering (IMRX) Stock Up 24% Today?
↗
August 01, 2024
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.
Via
InvestorPlace
Top Trade Picks Of The Day: Don’t Miss These Market Movers
↗
December 17, 2024
Discover today’s top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens.
Via
Talk Markets
Topics
Stocks / Equities
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 17, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
↗
December 13, 2024
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
Via
Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 12, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
November 27, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 15, 2024
Via
Benzinga
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024
From
Immuneering Corporation
Via
GlobeNewswire
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
↗
October 02, 2024
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.
Via
Benzinga
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
↗
September 13, 2024
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate...
Via
Benzinga
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
↗
August 01, 2024
Via
Benzinga
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
↗
August 01, 2024
Via
Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 31, 2024
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 11, 2024
Via
Benzinga
Immuneering to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Immuneering Corporation
Via
GlobeNewswire
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
↗
May 07, 2024
IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
May 07, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Recognizes Melanoma Awareness Month
May 06, 2024
From
Immuneering Corporation
Via
GlobeNewswire
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024
From
Immuneering Corporation
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
